Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 7.4% Potential Upside Indicated by JP Morgan Cazenove

Hikma Pharmaceuticals Plc 7.4% Potential Upside Indicated by JP Morgan Cazenove

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘NEUTRAL’ today by analysts at JP Morgan Cazenove. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. JP Morgan Cazenove have set their target price at 1700 GBX on its stock. This now indicates the analyst believes there is a possible upside of 7.4% from the opening price of 1582.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 138 points and decreased 188 points respectively. The 1 year high share price is 2089 GBX while the year low stock price is currently 906.2 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,668.09 GBX and a 200 day moving average of 1,732.49. There are currently shares in issue with the average daily volume traded being 566,684. Market capitalisation for LON:HIK is £3,804,324,196 GBP.